Gilead and Merck announced mixed clinical trial results, discontinuing a Phase 3 study for non-small cell lung cancer due to disappointing outcomes. Conversely, the companies reported that Phase 3 trials for a once-weekly oral HIV treatment regimen met their primary efficacy endpoints with a safety profile comparable to existing treatments. Plans are underway to submit this data to global regulatory authorities and present detailed findings at an upcoming scientific congress.
